Relmada Raises $3M to Develop LevoCap Painkiller
Relmada Therapeutics today announced that $3 million in Series A proceeds from stakeholders and investors will be used to continue the development of the opioid LevoCap.
Providing a once-daily extended release dosage of levorphanol, LevoCap is intended to treat chronic pain and potentially reverse a patient's analgesic tolerance to morphine.
Relmada anticipates launching a Phase 3 study for the drug in 2013, according to CEO Sergio Traversa.
Related Articles on Pain Management:Middle Fork Surgery Center Visited by Oregon's Co-Speaker of the House
Dr. Daniel Carr Named PAINWeek 2012 Keynote Speaker
Neurostimulation Field Draw Investor Attention
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.